Prospective, comparative study on cost-effectiveness of home-based motor monitoring system and office-based medical assessment in advanced Parkinson´s disease (P1.202)

Objective: To compare the cost-effectiveness of two cohorts of patients with Parkinson´s disease (PD), one group using home-based motor monitoring system (HBMMS) to facilitate patient care every month, and the other receiving the standard office-based patient care (OBPC) every 4 months. Background: There is a growing interest for tele-health care for chronic diseases. The cost-effectiveness of HBMMS in advanced PD is unknown. Procedure: Randomized, longitudinal pilot study. Motor and non motor symptoms (NMS) were assessed using the UPDRS, Hoehn Yahr stage, and NMS-questionnaire. A standardized questionnaire was used to collect cumulative medical and non medical direct costs (DC) over the last 4 months. The incremental cost-effectiveness ratio (ICER) expressing cost per additional unit of UPDRS total score improvement, was calculated. Results: Results: 40 patients were included (20 from each group) with a mean age of 66.4 years old + 8.4, 55[percnt] women, mean UPDRS total score of 56.2 + 18.3, median HY stage of 2 (2-3) . At baseline both groups were homogeneous in terms of DC, age, gender, and UPDRS motor scores. Compared to baseline assessments, only patients receiving HBMMS had lower UPDRS II scores (p=0.03), 8 months later. In the HBMMS group, the mean UPDRS total score difference (last visit-baseline visit) was improved (-2.5 ±16.9), and the mean DC difference was reduced (-1665.2 € ±3138.1). In contrast in the OBPC group, the UPDRS total score worsened (+3.1 ±15.4), as well as DC (+121.0 € ±3302.3). In the HBMMS patients, the ICER needed to obtain an improvement of one point in the UPDRS total score was 313.9 €. Conclusions: The economic burden of direct medical and non medical costs in advanced PD can be ameliorated by using tele-health care. An ICER/UPDRS of 313.9 € is within appropriate limits to consider tele-health care an efficient intervention. Disclosure: Dr. Cubo Delgado has received personal compensation for activities with Abbott and UCB Pharma. Dr. Mariscal-Perez has nothing to disclose. Dr. Solano has nothing to disclose. Dr. Becerra has nothing to disclose. Dr. Arribas has nothing to disclose.